Did New Zoliflodacin Data and FDA Review Just Shift Innoviva’s (INVA) Investment Narrative?
- Innoviva Specialty Therapeutics recently announced it will present six data sets, including subgroup results from the Phase 3 zoliflodacin trial for uncomplicated gonorrhea, at IDWeek 2025, with ongoing FDA review and multiple antibiotic portfolio updates highlighted.
- The company’s collaboration with the Global Antibiotic Research & Development Partnership on zoliflodacin signals advancing efforts against antibiotic-resistant infections and may influence clinical practice and regulatory landscapes.
- We’ll explore how new clinical data and the FDA review for Innoviva’s lead antibiotic candidate could shift its long-term investment story.
We’ve found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full…
